Trial reportNaunyn-Schmiedeberg's archives of pharmacology2026
Safety and tolerability of the ACE-inhibitor lisinopril among Nigerian adults with HIV: preliminary pilot data from a randomized clinical trial.
Trial report in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
We report preliminary safety and tolerability data from 66 persons living with HIV (PLWH) (≥ 18 years old) who received escalating dosages of lisinopril or matched placebo, in addition to antiretroviral therapy in northern Nigeria. We monitored for adverse events (AEs) by reviewing patient history, laboratory data, and clinic data at each follow-up visit. We then characterized all AEs in terms of "relatedness" to study intervention and graded based on severity (1-5 grading scale) using the Division of AIDS Toxicity Grading Scale, version 2.1. For this study, we monitored 66 participants over 7 months. Among 33 participants on lisinopril, 14 (42.4%) remained on 5 mg/day while 19 (57.6%) tolerated ≥ 10 mg/day. Forty-one AEs occurred in 31 participants, with 19 (61.3%) on lisinopril. The majority, 37 (90.2%) of the AEs were Grade 1 or 2 in severity. Hypotension was most frequent in the Lisinopril group (4 (12.1%) vs. 2 (6.1%) in placebo), occurring at 10 mg. Persistent cough occurred in 3 (9.1%) Lisinopril recipients vs. 2 (6.1%) placebo, all at 5 mg. In 2 (66.7%) of the 3 Lisinopril recipients, the cough persisted leading to unblinding and a switch to Losartan. The most serious AE was angioedema that occurred in one participant receiving 5 mg Lisinopril, requiring unblinding and discontinuation. Transient kidney function worsening (eGFR < 60 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.